Regulation of genes associated with angiogenesis, growth, and metastasis by specific p53 point mutations in a murine melanoma cell line

Oncology Reports

Volumn 4, Issue 3, 1997, Pages 475-179

  Koura, Aaryan N ^a   Van Golen, Kenneth ^a   Tsan, Rachel ^a   Radinsky, Robert ^a   Price, Janet E ^a   Ellis, Lee M ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

angiogenesis; growth factors; melanoma; metastasis; p53

Indexed keywords

PROTEIN P53;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL GROWTH; CELL LINE; CONTROLLED STUDY; GENETIC REGULATION; MELANOMA; METASTASIS; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL;

EID: 0030915222     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.3.475     Document Type: Article

References (36)

1. Harris A: p53-the commonest genetic alteration in human cancer. Am J Pathol 162: 5-6, 1990.
2. Miller C, Chumakov A, Said J, Chen D, Aslo A and Koeffler H: Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8: 1815-1824, 1993.
3. Dix B, Robbins P, Carrello S, House A and Iacopetta B: Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 70: 585-590, 1994.
4. Starzynaska T, Bromley M, Ghosh A and Stern P: Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66: 558-562, 1992.
5. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E and Pozza F: Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454-466, 1994.
6. van Golen K: Involvement of human chromosome 17 in the control of the metastatic phenotype in melanoma. University of Texas, Health Sciences Center at Houston, Graduate School of Biomedical Sciences, Cell Biology, Houston, TX, Ph.D. Thesis, 1996.
7. Petch L, Harris J, Raymond V, Blasband A, Lee D and Earp H: A truncated secreted form of EGF-R is encoded by an alternatively spliced transcript in normal rat tissue. Mol Cell Biol 10: 2973-2982, 1990.
8. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, et al: Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 12: 5152-5158, 1992.
9. Oliner J, Kinzler K, Meltzer P, George D and Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 15-16, 1992.
10. Connolly D, Heuvelman D, Nelson R, Olander J, Eppley B, Delfino J, Siegel N, Leimgruber R and Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84: 1470-1478, 1989.
11. Takahashi Y, Kitadai Y, Bucana C, Cleary K and Ellis L: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968, 1995.
12. Potgens AJ, Altena MCV, Lubsen NH, Ruiter DJ and Waal RMD: Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. Am J Pathol 148: 1203-1217, 1996.
13. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ and Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172-181, 1996.
14. Norgaard P, Hougaard S, Poulsen H and Spang-Thomsen M: Transforming growth factor β and cancer. Cancer Treatment Rev 21: 367-403, 1995.
15. Liotta L, Kleinerman J and Saldel G: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34: 997-1004, 1974.
16. Kieser A, Weich HA, Brandner G, Marme D and Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor. Oncogene 9: 963-969, 1994.
17. Mukhopadhyay D, Tsiokas L and Sukhatme VP: Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55: 6161-6165, 1995.
18. Rusciano D, Lorenzoni P and Burger MM: Expression of constitutively activated hepatocyte growth factor (c-met) in B16 melanoma cells selected for enhanced liver colonization. Oncogene 11: 1979-1987, 1995.
19. Rong S, Donehower LA, Hansen MF, Strong L, Tainsky M, Jeffers M, Resau JH, Hudson E, Tsarfaty I and Woude GFV: Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 55: 1963-1970, 1995.
20. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL and Cuttitta F: Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271: 11477-11483, 1996.
21. Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA and Schiffmann E: The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem 264: 21544-21549, 1989.
22. Tricoli J, Rall L, Karakousis C, Herrera L, Petrelli N, Bell G and Shows T: Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 46: 6169-6173, 1986.
23. Werner H, Karnieli E, Rauscher FJ and LeRoith D: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93: 8318-8323, 1996.
24. Barbareschi M, Girlando S, Fellin G, Graffer U, Luciani L and Palma P: Expression of mdm-2 and p53 protein in transitional cell carcinoma. Urol Res 22: 349-352, 1995.
25. Bueso-Ramos C, Manshouri T, Haidar M, Huh Y, Keating M and Albitar M: Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk Lymphoma 17: 13-18, 1995.
26. Dameron KM, Volpert OV, Tainsky MA and Bouk N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1502-1504, 1994.
27. Tuszynski G, Gasic T, Rothman V, Knudsen K and Gasic G: Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47: 4130-4133, 1987.
28. Wang TN, Qian X-H, Granick MS, Solomon MP, Rothman VL, Berger DH and Tuszynski GP: Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer. J Surg Res 63: 39-43, 1996.
29. Tuszynski G, Smith M, Rothman V, Capuzzi D, Joseph R, Katz J, Besa E, Treat J and Switalska H: Thrombospondin levels in patients with malignancy. Thromb Haemost 67: 607-611, 1992.
30. Radinsky R: Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 14: 323-338, 1995.
31. Modjtahedi H and Dean C: The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int J Oncol 4: 277-296, 1994.
32. Rusch V, Klimstra D, Linkov I and Dmitrovsky E: Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 55: 1365-1372, 1995.
33. Deb SP, Munoz RM, Brown DR, Subler MA and Deb S: Wild-type human p53 activates the human epidermal growth factor receptor promotor. Oncogene 9: 1341-1349, 1994.
34. Zambetti G and Levine AA: Comparison of the biological activities of wild-type and mutant p53. FASEB J 7: 855-865, 1993.
35. Halevy O, Michalovitz D and Oren M: Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250: 113-116, 1990.
36. Lee CS, Pirdas A and Lee MW: p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis. Australas J Dermatol 36: 192-195, 1995.